PATENT CLAIM ANALYSIS

Application Number: 15897138
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "264100"]

Abstract:
The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.

Claim (Index 1):
A method of treating a neurodegenerative disease, comprising the step of: administering trametinib to a patient diagnosed with the neurodegenerative disease.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 88.0
- Lexical Diversity: 2.18868
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15455954', '14181285', '14913549', '10976699', '12095723']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7732209966299002
- 35 USC 102 Novelty (BERT): 0.5289437499186278
- Combined Prediction Score: 0.748793271958773
- Mean Citation Score: 298.1416420000001
- Max Citation Score: 354.8590000000001
- Similarity Product: 269.0444240601064

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test